Is Evotec SE (EVO) a Buy, Sell, or Hold?
NASDAQ : EVO
Evotec SE
$1.98 USD
$0.03 (1.54%)
- Volume
- 46.69K
- Average Volume
- 64.52K
- Market Capitalization
- $703.27M
- P/E Ratio
- -3.19
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $4.42
- Year Low
- $1.94
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.68
Company Overview
NASDAQ
Christian Wojczewski
Drug Manufacturers - Specialty & Generic
Healthcare
EVO
4526
DE
USD
Liquidity Metrics
0.55
1.68
1.60
0.92
0.00
Sales & Valuation
$757.26M
0.83
0.88
-14.55
-0.12
Profitability
-$0.28
-$99.43M
-26.02%
-24.04%
-24.55%
-11.82%
P/E Metrics
-3.19
0.04
0.04
Analyst Price Target & Rating
$3.00
$4.00
$2.00
1/5
7 Analysts
-34.00%
Financial Health Scores
-0.03
4/9
$288.2M
$1.64B
$941.17M
-$160.21M
Key Metrics (TTM)
$602.33M
0.81
-15.61
1.68
-24.55%
-7.93%
-32.17%
-7.03%
70 days
Company Executives
| Name | Title |
|---|---|
| Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations |
| Cord Dohrmann | Chief Scientific Officer & Member of Management Board |
| Uwe Andag | EVP Head of Metabolic Diseases |
| David Hallet | Executive Vice President |
| Claire Hinshelwood | Chief Financial Officer & Member of Management Board |
| Christian Wojczewski | CEO & Chairperson of the Management Board |
| Ian Hunneyball | Senior Vice President of Programme Management & Clinical Operations |
| Ingrid Mller | Chief Operating Officer & Member of Management Board |
| Aurelie Dalbiez | Chief People Officer & Member of Management Board |
| Christian Dargel | EVice President Global Head of Legal & Compliance |
Poll Results
No votes yet today — be the first to share your view!
About Evotec SE (NASDAQ:EVO) Stock
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squ ... ibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
2026-07-23 03:00:00
PALO ALTO, Calif.--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independentl.
Evotec SE (EVO) Q2 2026 Earnings Call Transcript
2026-07-14 11:29:06
Evotec SE (EVO) Q2 2026 Earnings Call Transcript
Evotec Q2 Earnings Call Highlights
2026-07-14 09:03:38
Evotec NASDAQ: EVO reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements.
2026-07-13 16:00:00
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook PR Newswire
2026-07-13 15:43:00
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook.
Evommune's Healthy Balance Sheet Buys Them Time For AD
2026-07-01 07:15:23
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
2026-06-30 03:00:00
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics PR Newswire S
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics
2026-06-30 02:16:00
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform Enables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturing Modular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturing SEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion.
Frequently Asked Questions
-
What is the current Evotec SE (EVO) stock price?
-
Evotec SE(NASDAQ:EVO) stock price is $1.98 in the last trading session. During the trading session, EVO stock reached the peak price of $4.42 while $1.94 was the lowest point it dropped to. The percentage change in EVO stock occurred in the recent session was 1.54% while the dollar amount for the price change in EVO stock was $0.03.
-
EVO's industry and sector of operation?
-
The NASDAQ listed EVO is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of EVO?
-
Sarah Fakih | Executive VP, Head of Global Communications & Investor Relations
Cord Dohrmann | Chief Scientific Officer & Member of Management Board
Uwe Andag | EVP Head of Metabolic Diseases
David Hallet | Executive Vice President
Claire Hinshelwood | Chief Financial Officer & Member of Management Board -
How many employees does EVO have?
-
Number of EVO employees currently stands at 4526. EVO operates from Essener Bogen 7, Hamburg, HA 22419, DE.
-
Link for EVO official website?
-
Official Website of EVO is: https://www.evotec.com
-
How do I contact EVO?
-
EVO could be contacted at phone #49 40 560 81 0 and can also be accessed through its website. EVO operates from Essener Bogen 7, Hamburg, HA 22419, DE.
-
How many shares of EVO are traded daily?
-
The average number of EVO shares traded daily for last 3 months was 64.52K.
-
What is the market cap of EVO currently?
-
The market value of EVO currently stands at $703.27M with its latest stock price at $1.98